Abstract
Purpose:
To describe a new approach for the treatment of cyclitic vascularized pupillary membranes.
Patients and methods:
A retrospective interventional case series describing 3 patients undergoing a novel interventional treatment at a single institutional center.
Results:
This technique allows successful completion of laser membranectomy to create a pupillary aperture. This aperture resulted in improved vision and an enhanced ability to examine for and treat ischemic retinal disease.
Conclusions:
This technique describes a new use for bevacizumab that enables the surgeon to treat recalcitrant and recurrent cyclitic vascularized pupillary membranes.
MeSH terms
-
Aged
-
Angiogenesis Inhibitors / therapeutic use*
-
Anterior Eye Segment / blood supply*
-
Bevacizumab / therapeutic use*
-
Combined Modality Therapy
-
Eye Abnormalities / drug therapy
-
Eye Abnormalities / surgery
-
Eye Abnormalities / therapy*
-
Female
-
Humans
-
Intravitreal Injections
-
Laser Coagulation*
-
Lasers, Solid-State / therapeutic use*
-
Male
-
Middle Aged
-
Neovascularization, Pathologic / drug therapy
-
Neovascularization, Pathologic / surgery
-
Neovascularization, Pathologic / therapy*
-
Retrospective Studies
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Visual Acuity
Substances
-
Angiogenesis Inhibitors
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
Supplementary concepts
-
Pupillary Membrane, Persistence Of